The objective of this proposal is to enable investigators at Children's National Medical Center (CNMC) to conduct investigations of the therapy, biology, and causes of malignant disease in infants, children and adolescents through participation in the Children's Cancer Group (CCG) and to provide scientific and administrative leadership of such studies. We propose to enter all eligible patients on Groupwide studies of multimodality therapy of acute leukemia and solid tumors. We propose to develop and conduct limited institution pilot (toxicity and/or feasibility) studies incorporating novel treatment strategies for childhood ALL, and dose-intensified treatments incorporating hematopoietic growth factors and stem cell transplantation. We propose to develop and conduct limited institution pilot studies of new agents and novel therapeutic approaches for the management of brain tumors and will continue to design and conduct clinical trials which pose questions of CNS pharmacologic interest. CNMC will continue as the most active CCG institution in the evaluation of new agents, both cytotoxic and biologic. We will participate in correlative pharmacology and biology studies. We will comply with protocol-specified therapy as well as required evaluations and will submit complete and accurate data to the Operations Office in a timely fashion. CNMC will continue as a performance site of the CCG ALL Biology Reference Laboratory for the identification of appropriate patients for biotherapeutic studies incorporating monoclonal antibodies to leukemia cell associated antigens to identify specific immunotoxins for immunotherapeutic classes of disease. This laboratory will lead the effort to evaluate the efficacy of new classes of agents in acute lymphoblastic leukemia using a variety of preclinical models. Laboratory studies of the significance of the expression of the mdr-1 gene at diagnosis and correlation with functional assessment of multidrug resistance and clinical outcome will continue in homogeneously treated patient groups. We propose to continue investigation of the biological significance of shed tumor gangliosides in neuroblastoma, as well as the evaluation of differences in neuroblastoma membrane ganglioside patterns between patients identified through screening programs and patients with overt clinical disease. We propose to participate in case controlled epidemiologic studies of childhood cancer to investigate the possible relationship between genetic predisposition and pre- and post-natal environmental factors on the development of specific malignancies. We will participate in the formulation and conduct of quality of life evaluations to examine the long-term impact of successful anticancer therapy on all aspects of growth and development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA003888-45
Application #
6475714
Study Section
Subcommittee G - Education (NCI)
Program Officer
Smith, Malcolm M
Project Start
1976-12-01
Project End
2002-11-30
Budget Start
2001-12-01
Budget End
2002-11-30
Support Year
45
Fiscal Year
2002
Total Cost
$360,528
Indirect Cost
Name
Children's Research Institute
Department
Type
DUNS #
143983562
City
Washington
State
DC
Country
United States
Zip Code
20010
Baruchel, Sylvain; Pappo, Alberto; Krailo, Mark et al. (2012) A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. Eur J Cancer 48:579-85
Potter, Samara L Poplack; Berg, Stacey; Ingle, Ashish Mark et al. (2012) Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962). Pediatr Blood Cancer 58:362-5
Allen, Jeffrey; Donahue, Bernadine; Mehta, Minesh et al. (2009) A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931). Int J Radiat Oncol Biol Phys 74:1006-11
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Casillas, Jacqueline N; Woods, William G; Hunger, Stephen P et al. (2003) Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia: a report from the Children's Cancer Group. J Pediatr Hematol Oncol 25:594-600
Davies, Stella M; Bhatia, Smita; Ross, Julie A et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100:67-71
Wells, Robert J; Reid, Joel M; Ames, Matthew M et al. (2002) Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatr Hematol Oncol 24:89-93
Lange, Beverly J; Bostrom, Bruce C; Cherlow, Joel M et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-33
Ou, Shu Xiao; Han, Dehui; Severson, Richard K et al. (2002) Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control 13:15-25
Cairo, M S; Krailo, M D; Morse, M et al. (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia 16:594-600

Showing the most recent 10 out of 25 publications